LABORIE completed its acquisition of BUCK Elektromedizin GmbH and BUCKmeditec GmbH & Co. BUCK, headquartered in Bad Rappenaeau, Germany, develops and distributes innovative and advanced Biofeedback and electrical stimulation equipment, accessories and consumables for pelvic floor dysfunction in the treatment of Urinary and Fecal incontinence.
“Both LABORIE and BUCK have a shared commitment to helping healthcare professionals deliver better products and services, and to make life more rewarding and dignified for those who use our products,” stated Brian Ellacott, LABORIE President and CEO. “By combining existing product lines with BUCK’s extensive customer base, we can provide a greater breadth of innovative products and services to enable German urologists to deliver better care to their patients.”
LABORIE’s acquisition of BUCK further extends its market leadership in Pelvic Muscle Rehabilitation. The acquisition also expands LABORIE’s presence in the German market by adding 15 in-country sales representatives that will market the full range of both LABORIE and BUCK products.
BUCK managing director Franz Dettling said, “We are excited to partner with a global leader in urology who will help us expand the breadth of our offering to German urologists as well as help provide access to our unique pelvic therapy offerings around the world.”
LABORIE (www.laborie.com), headquartered in Toronto, Canada, is a leading global developer, manufacturer and marketer of innovative medical technology and consumables used for the diagnosis and treatment of Urinary and Fecal Incontinence, as well as other pelvic floor disorders in the Urology, Gynecology, and Colorectal fields.
Laborie Medical Technologies Inc. (LABORIE), a leading diagnostic and therapeutic medical technology company, today announced the first Optilume® procedures were performed in the UK at NHS Trust on June 11, 2021 by Dr. Pareeta Patel and Professor. Nick Watkin.
Laborie Medical Technologies Inc. (LABORIE), a leading diagnostic and therapeutic medical technology company, today announced the first Optilume® procedures were performed in Mannheim, Germany on January 22, 2021 by Dr. Georgi Tosev (Mannheim Urology).
Transaction demonstrates LABORIE’s commitment to providing innovative solutions to urologists globally LABORIE to invest $15 million in Urotronic Series C financing LABORIE secures option to acquire Urotronic’s Optilume™ technology